
Dynamic evaluation of MRI-targeted, systematic and combined biopsy for prostate cancer diagnosis through 10 years of practice in a single institution

LENFANT ET AL, WORLD JOURNAL OF UROLOGY (APRIL 2022)






PATIENTS & METHODS



RESULTS



- More significant cancers Fewer insignificant cancers
- Clinically significant cancer detection x2.5 in 10 years from 23% to 58%.
- Clinically insignificant cancer decreases to <20% ratio by ruling out negative MRI in 2015.
- Results obtained with more targeted, less systematic biopsy cores over years.

KEY TAKE AWAY

- A new prostate biopsy standard has been validated over 10 years in a single academic institution.
- Evidencing the efficacy of a KOELIS-guided targeted+systematic scheme after positive MRI.
- In maximizing detection of clinically significant cancer and minimizing unsignificant cancer,

